Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
about
Metabolomics: Bridging the Gap between Pharmaceutical Development and Population HealthIntegration of Mitochondrial Targeting for Molecular Cancer TherapeuticsCancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasionPI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.Mitochondrial Akt Regulation of Hypoxic Tumor ReprogrammingAMPK activity regulates trafficking of mitochondria to the leading edge during cell migration and matrix invasion.Global transcriptomic analysis of induced cardiomyocytes predicts novel regulators for direct cardiac reprogramming.Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma.Disabling mitochondrial reprogramming in cancerMolecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer.Impaired pentose phosphate pathway in the development of 3D MCF-7 cells mediated intracellular redox disturbance and multi-cellular resistance without drug induction.Drug repurposing for the treatment of glioblastoma multiforme.The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.Mitochondria and Cancer.Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.β-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCCMitochondrial metabolism and cancer
P2860
Q26741270-FC825AA4-8DCF-41F2-BC54-C24B2E64C9D5Q26771751-B33DAFCC-48C2-480F-8809-DD4AAC345466Q26796364-93A519AA-0AC4-4867-A0D6-BC41F2F37486Q27324467-0D07E0CC-8E0C-468B-94A3-62A77367E02DQ28771755-3738BE60-1CC3-4309-84DE-BE359449118DQ30806095-80CEE70D-48E6-4B29-A4C5-F40743E256B2Q33714759-021FA731-EBD6-4B60-A4A3-BFCDAFCFDB34Q33829265-4462AE1F-6BEF-40AF-AE35-97E35A94C5C1Q36232092-1DABB8E2-1801-4D9A-8546-D7F518C8213CQ36385108-B6A02299-C4D1-4995-966E-8DEA465B5CAEQ36535726-CD8475B6-E1F0-493D-BADF-4BB82A5D5FD3Q36732781-98AB2380-0BD8-4DF9-BAE0-D1350C087F0FQ37660266-52B2B8A3-4F3A-4D5B-A8B2-3680EAA5B62AQ37717138-6B28DBE2-3658-408B-9989-5C0E7375454EQ38796931-65057E1F-9A34-4ED5-A654-3672E7CD8244Q41043950-406E5426-FA36-4610-B00C-86A318488196Q42330188-FEB87332-1753-4052-88F0-C4F205FB16E1Q42652909-760617F0-2637-47A4-97E6-D77A60755AB2Q47115416-E262B015-75A9-4563-942B-0B3E695A176CQ47127243-F96A3248-006C-4DC9-AB34-1FB79DB4452AQ47162272-1A998F32-FE75-4931-8FC6-7B79896A81C5Q47804995-CBD39477-6C7D-4B93-9841-799C9C023D2EQ47948290-9891E31D-1577-4A2F-8C49-0645C528321CQ49887915-0A458B4B-FA88-491F-9867-288684C73E0FQ53198693-D23DE37A-F6A2-4726-98CC-1DAA889D426DQ55263786-6EDF1DCE-4BE1-408F-A763-EA99A5A03A85Q57295721-AC187851-73BC-4A4F-AF77-08088337D498Q57842307-955BA541-DC40-491D-BCD9-DE4B2B4F5CC3
P2860
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
@ast
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
@en
type
label
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
@ast
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
@en
prefLabel
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
@ast
Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
@en
P2093
P2860
P50
P356
P1476
Adaptive mitochondrial reprogramming and resistance to PI3K therapy
@en
P2093
Andrew V Kossenkov
Dario C Altieri
David C Schultz
Jae Ho Seo
Jagadish C Ghosh
Markus D Siegelin
Massimo Giroda
Michele Tavecchio
Paolo Rampini
Ryan D Michalek
P2860
P356
10.1093/JNCI/DJU502
P407
P577
2015-02-03T00:00:00Z